Applied Therapeutics (APLT) has disclosed a new risk, in the Accounting & Financial Operations category.
Applied Therapeutics has disclosed a significant deficiency in their financial reporting mechanisms, pinpointing a material weakness in their internal controls specifically during the financial statement close process for the year ending December 31, 2023. This flaw pertains to the insufficient review of complex accounting matters requiring substantial judgment, raising concerns about the potential for material misstatements in their financial disclosures. Despite efforts to remedy these issues, there is no guarantee of success, and the persistence or emergence of such weaknesses could undermine investor trust, diminish stock value, and lead to non-compliance with regulatory filing requirements.
The average APLT stock price target is $11.25, implying 69.94% upside potential.
To learn more about Applied Therapeutics’ risk factors, click here.
